Ejima J, Kaneda K, Moriyama H, Ohmura I, Maruyama T, Kaji Y, Tsuda Y, Kanaya S, Fujino T, Niho Y
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Jpn Heart J. 1995 Nov;36(6):699-707. doi: 10.1536/ihj.36.699.
Although nicorandil, N-(2-hydroxyethyl) nicotinamide dinitrate, is a nitrate ester, its cardiovascular action differs from that of nitrate compounds in several aspects. In this quantitative angiographic study, the acute coronary dilating effect of intracoronary nicorandil (0.25, 0.50, 1.0 mg) was compared with that of isosorbide dinitrate (ISDN; 1.0 mg) in 46 patients with or without ischemic heart disease (IHD). Dose-dependent right coronary dilating action was observed by intracoronary administration of nicorandil without any adverse effects. The same degree of right coronary dilation was achieved by the intracoronary application of equivalent doses of ISDN. We conclude that intracoronary administration of nicorandil is beneficial for the supportive treatment of IHD during coronary artery investigation and intervention without the risk of severe systemic hypotension.
尽管尼可地尔（N-(2-羟乙基)烟酰胺二硝酸盐）是一种硝酸酯类药物，但其心血管作用在几个方面与硝酸盐类化合物不同。在这项定量血管造影研究中，对46例有或无缺血性心脏病（IHD）的患者，比较了冠状动脉内注射尼可地尔（0.25、0.50、1.0毫克）与硝酸异山梨酯（ISDN；1.0毫克）的急性冠状动脉扩张作用。冠状动脉内注射尼可地尔可观察到剂量依赖性的右冠状动脉扩张作用，且无任何不良反应。冠状动脉内应用等效剂量的ISDN可实现相同程度的右冠状动脉扩张。我们得出结论，冠状动脉内注射尼可地尔有利于在冠状动脉检查和干预期间对IHD进行支持治疗，而无严重全身性低血压的风险。
